During the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more. The medicine, used to treat an aggressive form of the disease, ...
Two recent studies offer hope of enhancing both the effectiveness and safety of Herceptin, the drug that helped introduce the era of targeted therapy. Two studies presented Saturday offer hope of ...
Herceptin Indication Statements Adjuvant Breast Cancer Herceptin is approved for the treatment of early stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive (HER2-positive ...
BRUSSELS - The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage ...
HERA (HERceptin Adjuvant) Trial Recruitment Begins One of the largest ever breast cancer studies to look at the benefits of Herceptin® (trastuzumab) in Adjuvant Breast Cancer 11th European Cancer ...
– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...
SAN ANTONIO—Roche is in the hot seat as its longtime breast cancer blockbuster Herceptin faces a growing stable of biosimilar challengers. But other drugs in Roche's portfolio are on the rise: Look at ...
Dear Doctors: I've been diagnosed with breast cancer and really appreciate your recent columns on the subject. What can you tell me about Herceptin? My oncologist has suggested it for after ...
The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback